Fasting diets show promise in enhancing mood, sleep, and eating behaviors

John­son & John­son’s oral IL-23 that it li­censed from Pro­tag­o­nist Ther­a­peu­tics ap­pears to be a weak­er pso­ri­a­sis treat­ment than some of its in­jectable com­pe­ti­tion, ac­cord­ing

The two-component therapy is indicated for adults living with late-onset Pompe disease. Credit: Jensflorian/commons.wikimedia.org. Amicus Therapeutics has received approval from the US Food and Drug